GLOBUS MEDICAL INC - A (GMED) Stock Fundamental Analysis
USA - NYSE:GMED - US3795772082 - Common Stock
59.909 USD
-0.51 (-0.85%)
GMED gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. GMED gets an excellent profitability rating and is at the same time showing great financial health properties. GMED is not valued too expensively and it also shows a decent growth rate. This makes GMED very considerable for quality investing!
1. Profitability
1.1 Basic Checks
GMED had positive earnings in the past year.
GMED had a positive operating cash flow in the past year.
GMED had positive earnings in each of the past 5 years.
In the past 5 years GMED always reported a positive cash flow from operatings.
1.2 Ratios
GMED has a better Return On Assets (7.19%) than 89.53% of its industry peers.
With an excellent Return On Equity value of 8.30%, GMED belongs to the best of the industry, outperforming 82.72% of the companies in the same industry.
GMED's Return On Invested Capital of 9.00% is amongst the best of the industry. GMED outperforms 88.48% of its industry peers.
The Average Return On Invested Capital over the past 3 years for GMED is in line with the industry average of 9.00%.
The 3 year average ROIC (7.50%) for GMED is below the current ROIC(9.00%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.19% | ||
| ROE | 8.3% | ||
| ROIC | 9% |
ROA(3y)4.51%
ROA(5y)5.45%
ROE(3y)5.28%
ROE(5y)6.24%
ROIC(3y)7.5%
ROIC(5y)7.39%
1.3 Margins
Looking at the Profit Margin, with a value of 13.58%, GMED belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
GMED's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 19.48%, GMED belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
GMED's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 68.97%, GMED is doing good in the industry, outperforming 76.44% of the companies in the same industry.
In the last couple of years the Gross Margin of GMED has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.48% | ||
| PM (TTM) | 13.58% | ||
| GM | 68.97% |
OM growth 3Y-4.88%
OM growth 5Y-4.91%
PM growth 3Y-35.97%
PM growth 5Y-27.03%
GM growth 3Y-3.49%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), GMED is creating some value.
The number of shares outstanding for GMED has been increased compared to 1 year ago.
The number of shares outstanding for GMED has been increased compared to 5 years ago.
Compared to 1 year ago, GMED has a worse debt to assets ratio.
2.2 Solvency
GMED has an Altman-Z score of 8.89. This indicates that GMED is financially healthy and has little risk of bankruptcy at the moment.
GMED has a Altman-Z score of 8.89. This is amongst the best in the industry. GMED outperforms 89.53% of its industry peers.
The Debt to FCF ratio of GMED is 0.00, which is an excellent value as it means it would take GMED, only 0.00 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of GMED (0.00) is better than 95.29% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that GMED is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, GMED is in the better half of the industry, outperforming 75.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.89 |
ROIC/WACC1.05
WACC8.54%
2.3 Liquidity
GMED has a Current Ratio of 4.07. This indicates that GMED is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.07, GMED is in the better half of the industry, outperforming 70.16% of the companies in the same industry.
A Quick Ratio of 2.26 indicates that GMED has no problem at all paying its short term obligations.
GMED has a Quick ratio (2.26) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.07 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
GMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.59%, which is quite impressive.
Measured over the past years, GMED shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.19% on average per year.
GMED shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.44%.
Measured over the past years, GMED shows a very strong growth in Revenue. The Revenue has been growing by 26.25% on average per year.
EPS 1Y (TTM)21.59%
EPS 3Y15.46%
EPS 5Y13.19%
EPS Q2Q%14.67%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y38.03%
Revenue growth 5Y26.25%
Sales Q2Q%18.37%
3.2 Future
The Earnings Per Share is expected to grow by 12.10% on average over the next years. This is quite good.
GMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.25% yearly.
EPS Next Y4.19%
EPS Next 2Y9.07%
EPS Next 3Y10.4%
EPS Next 5Y12.1%
Revenue Next Year14.06%
Revenue Next 2Y10.99%
Revenue Next 3Y9.56%
Revenue Next 5Y7.25%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 18.66, the valuation of GMED can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of GMED indicates a rather cheap valuation: GMED is cheaper than 80.10% of the companies listed in the same industry.
GMED is valuated rather cheaply when we compare the Price/Earnings ratio to 27.91, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 16.04, the valuation of GMED can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GMED indicates a rather cheap valuation: GMED is cheaper than 83.77% of the companies listed in the same industry.
GMED's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.30.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.66 | ||
| Fwd PE | 16.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMED indicates a rather cheap valuation: GMED is cheaper than 89.53% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GMED indicates a rather cheap valuation: GMED is cheaper than 91.62% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.49 | ||
| EV/EBITDA | 10.12 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GMED does not grow enough to justify the current Price/Earnings ratio.
GMED has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)4.46
PEG (5Y)1.41
EPS Next 2Y9.07%
EPS Next 3Y10.4%
5. Dividend
5.1 Amount
GMED does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:GMED (10/9/2025, 1:01:39 PM)
59.909
-0.51 (-0.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners103.37%
Inst Owner Change0%
Ins Owners0.68%
Ins Owner Change-1.33%
Market Cap8.09B
Analysts76.19
Price Target84.2 (40.55%)
Short Float %5.91%
Short Ratio4.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.6%
Min EPS beat(2)-10.39%
Max EPS beat(2)11.6%
EPS beat(4)3
Avg EPS beat(4)9.28%
Min EPS beat(4)-10.39%
Max EPS beat(4)25.45%
EPS beat(8)5
Avg EPS beat(8)8.04%
EPS beat(12)8
Avg EPS beat(12)5.67%
EPS beat(16)11
Avg EPS beat(16)4.32%
Revenue beat(2)0
Avg Revenue beat(2)-3.9%
Min Revenue beat(2)-6.31%
Max Revenue beat(2)-1.49%
Revenue beat(4)2
Avg Revenue beat(4)-1.52%
Min Revenue beat(4)-6.31%
Max Revenue beat(4)1.57%
Revenue beat(8)4
Avg Revenue beat(8)-2.13%
Revenue beat(12)6
Avg Revenue beat(12)-1.07%
Revenue beat(16)7
Avg Revenue beat(16)-1.09%
PT rev (1m)0%
PT rev (3m)-3.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.69%
EPS NY rev (1m)0%
EPS NY rev (3m)1.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.09%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.66 | ||
| Fwd PE | 16.04 | ||
| P/S | 3.08 | ||
| P/FCF | 15.49 | ||
| P/OCF | 12.09 | ||
| P/B | 1.88 | ||
| P/tB | 3.92 | ||
| EV/EBITDA | 10.12 |
EPS(TTM)3.21
EY5.36%
EPS(NY)3.74
Fwd EY6.24%
FCF(TTM)3.87
FCFY6.46%
OCF(TTM)4.95
OCFY8.27%
SpS19.45
BVpS31.81
TBVpS15.28
PEG (NY)4.46
PEG (5Y)1.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.19% | ||
| ROE | 8.3% | ||
| ROCE | 11.28% | ||
| ROIC | 9% | ||
| ROICexc | 9.48% | ||
| ROICexgc | 19.67% | ||
| OM | 19.48% | ||
| PM (TTM) | 13.58% | ||
| GM | 68.97% | ||
| FCFM | 19.89% |
ROA(3y)4.51%
ROA(5y)5.45%
ROE(3y)5.28%
ROE(5y)6.24%
ROIC(3y)7.5%
ROIC(5y)7.39%
ROICexc(3y)9.36%
ROICexc(5y)9.51%
ROICexgc(3y)18.38%
ROICexgc(5y)15.86%
ROCE(3y)9.4%
ROCE(5y)9.26%
ROICexcg growth 3Y25.82%
ROICexcg growth 5Y11.96%
ROICexc growth 3Y-3.93%
ROICexc growth 5Y-4.62%
OM growth 3Y-4.88%
OM growth 5Y-4.91%
PM growth 3Y-35.97%
PM growth 5Y-27.03%
GM growth 3Y-3.49%
GM growth 5Y-2.63%
F-Score9
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 53.97% | ||
| Cap/Sales | 5.59% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.4% | ||
| Profit Quality | 146.48% | ||
| Current Ratio | 4.07 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 8.89 |
F-Score9
WACC8.54%
ROIC/WACC1.05
Cap/Depr(3y)69.29%
Cap/Depr(5y)78.11%
Cap/Sales(3y)5.6%
Cap/Sales(5y)6.16%
Profit Quality(3y)194.29%
Profit Quality(5y)172.4%
High Growth Momentum
Growth
EPS 1Y (TTM)21.59%
EPS 3Y15.46%
EPS 5Y13.19%
EPS Q2Q%14.67%
EPS Next Y4.19%
EPS Next 2Y9.07%
EPS Next 3Y10.4%
EPS Next 5Y12.1%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y38.03%
Revenue growth 5Y26.25%
Sales Q2Q%18.37%
Revenue Next Year14.06%
Revenue Next 2Y10.99%
Revenue Next 3Y9.56%
Revenue Next 5Y7.25%
EBIT growth 1Y203.64%
EBIT growth 3Y31.28%
EBIT growth 5Y20.06%
EBIT Next Year55.19%
EBIT Next 3Y24.18%
EBIT Next 5Y19.9%
FCF growth 1Y331.76%
FCF growth 3Y22.69%
FCF growth 5Y31.98%
OCF growth 1Y261.32%
OCF growth 3Y23.51%
OCF growth 5Y24.8%